Engflag

Fenleve

Quick links to important sections

Fenleve

There is no image.

Method of action: Analgesic, Analgetic, Anti-Inflammatory, Antipyretic, Nonsteroidal Anti-Inflammatory, Pain Reliever, Reducing Aggregation Of Platelets, Topical Products For Joint And Muscular Pain

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Pain, Pain, Back, Joint Pain, Bursitis, Gingivitis, Headache, Colic, Laryngitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenleve

What is Fenleve? Defining its Pharmaceutical Identity

Property Description
Active ingredient Ketoprofen
Form Oral capsules (including Modified-release formulation)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Symptomatic relief from pain, inflammation, and fever
Origin Synthetic compound / Propionic acid derivative

Defining Fenleve: Pharmaceutical Class and Identity

Fenleve is a medicinal preparation whose active ingredient is Ketoprofen, a compound officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This identity establishes it as a synthetic compound designed for systemic action against pain and inflammation throughout the body. The active substance, Ketoprofen, is chemically recognized as a Propionic acid derivative, sharing a foundational structure with other well-known analgesics in this class.

As a single-ingredient product, Fenleve’s pharmacological profile is strictly determined by the potent action of Ketoprofen, defining its core function as a strong anti-inflammatory agent and analgesic. Clinically recognized for its ability to inhibit prostaglandin synthesis, the medicine is commonly used in contexts where persistent discomfort requires management.

Composition, Origin, and Form

The medication is a synthetic compound formulated for oral administration, typically supplied in Oral capsules or specialized Modified-release formulation capsules, which serve as a distinctive feature for controlled drug delivery. These pharmaceutical preparations deliver the potent Ketoprofen into the systemic circulation via the gastrointestinal tract. The use of a modified-release formulation is engineered to control the rate at which Ketoprofen is released, helping to ensure that consistent therapeutic levels are maintained systemically over an extended period.

General Purpose: Symptomatic Relief and Benefits

The fundamental general purpose of Fenleve is to provide effective symptomatic relief by mitigating the primary symptoms of inflammation, pain, and fever. Ketoprofen functions as a potent Cyclooxygenase inhibitor, which is the high-level mechanism that blocks the formation of prostaglandins, thereby suppressing the body’s inflammatory and painful signaling pathways. This capability confirms the preparation's intended role in achieving overall symptomatic relief and providing robust pain management.

Regulatory References

  1. Ketoprofen - LiverTox - NIH

What side effects are possible with Fenleve?

Safety Map: Possible side effects and safety information for Fenleve

This structure presents the official safety profile of Fenleve (Ketoprofen) strictly based on governmental regulatory documentation (e.g., FDA Prescribing Information and EMA Summary of Product Characteristics).

Category Description / Official Entities
Key Adverse Reaction Categories Serious Cardiovascular Thrombotic Events (e.g., Myocardial Infarction, Stroke) and Serious Gastrointestinal Adverse Events (e.g., Bleeding, Ulceration, Perforation), which can be fatal.
Frequency Classification Common (1% to 10%): Dyspepsia, nausea, abdominal pain, diarrhea, headache, dizziness, and edema. Rare (0.01% to 0.1%): Peptic ulcer, severe hepatic reactions. Very Rare (<0.01%): Serious skin reactions (e.g., SJS, TEN).
System-Organ Classes Involved Gastrointestinal, Cardiovascular, Renal and Urinary, Hepatobiliary, Dermatological, and Nervous System.
Serious Adverse Reactions Fatal Gastrointestinal Bleeding and Perforation; Fatal Cardiovascular Thrombotic Events; Severe Hepatic Reactions (including Fulminant Hepatitis); Serious Skin Reactions (Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis); Severe Anaphylactic Reactions.
Population-Specific Safety Considerations Older Adults are documented as being at increased risk of serious GI adverse events. Pregnancy: Use is avoided in the last trimester due to potential risk to the fetus. Pediatrics (Under 18): Safety and effectiveness are generally not established for prescription products.
Dose- or Exposure-Related Patterns The risk of serious cardiovascular events may increase with duration of use and may occur early in treatment. Serious GI events can occur at any time during use and without warning symptoms.
Safety-Related Restrictions or Limitations Contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery. Contraindicated in patients with a history of aspirin-sensitive asthma. The medicine may impair female fertility.

Regulatory Safety Summary

  • Risk Foundation: The primary regulatory safety warnings center on the potential for rare but fatal cardiovascular and gastrointestinal events associated with the NSAID class.
  • Severity: Serious adverse events, including hepatic failure, severe skin reactions, and severe allergic reactions, are explicitly listed as rare but life-threatening possibilities.
  • Constraints: Absolute contraindications are defined, such as use in post-CABG pain and in individuals with aspirin-sensitive asthma, along with specific warnings for older adults and use during late pregnancy.

Connection to the overall safety profile:

The official safety information structures the risk profile by immediately foregrounding the potential for fatal cardiovascular and gastrointestinal events as the primary safety constraints. By detailing adverse reactions by System-Organ-Class and frequency, the profile provides a transparent map of both common effects and clinically significant complications. The explicit population-specific warnings and time-related patterns further define the safety conditions and limitations, as dictated by regulatory data.

Overdose and Emergency Response

Fenleve (Ketoprofen) overdose is officially described by regulatory agencies as presenting a spectrum of symptoms, ranging from acute gastrointestinal and central nervous system effects to severe, life-threatening outcomes. Documented manifestations may include epigastric pain, nausea, vomiting, lethargy, drowsiness, and headache. Less common, but officially noted, presentations include tinnitus and blurred vision.

In cases of over-ingestion, the regulatory profile highlights the potential for severe complications, such as gastrointestinal bleeding, acute renal failure, coma, seizures, and cardiovascular effects like hypotension. Large overdoses pose a serious risk to both adults and children.

Due to the documented risk of severe outcomes, the official guidance states that individuals must seek immediate medical help. The required emergency action is to call the national Poison Help hotline or local emergency services. Management is restricted to supportive and symptomatic care, as no specific antidote is known for Ketoprofen overdose. Procedural measures in a hospital setting may include gastric decontamination (such as activated charcoal, if clinically appropriate) and continuous monitoring. Monitoring may involve blood tests, an electrocardiogram (ECG), and endoscopy to check for internal bleeding, particularly for modified-release formulations.

Therapeutic Uses of Fenleve

What Fenleve Treats: Main Uses and Benefits

Fenleve is commonly used across conditions presenting with acute or disruptive episodes where additional symptomatic support is needed. It is relevant for easing the overall symptom burden, primarily in situations linked to inflammatory or irritative states.

The medication is applied in addressing symptom clusters that create noticeable physiological strain, notably in the symptomatic management of chronic conditions like rheumatoid arthritis and osteoarthritis, as well as during acute episodes such as gout flares, tendinitis, and postsurgical pain. It also is used for managing specific pain manifestations like primary dysmenorrhea and headache.

“This symptomatic support helps the patient cope more steadily with symptom fluctuations, may assist with maintaining functional stability.”

Fenleve supports the patient during difficult episodes by easing the distress of symptoms like persistent joint pain, swelling, and elevated body temperature. This action contributes to easing the overall symptom load during periods of heightened symptoms, which supports patients dealing with both long-term and temporary discomfort.

Quick Fact: Relief for Inflammation
Applied across: Symptomatic manifestations related to inflammatory conditions, soft tissue injuries, and rheumatic flare-ups.
Primary Benefit: Contributes to easing the overall symptom load by addressing pain and swelling.

Regulatory References

  1. NIH MedlinePlus overview of Ketoprofen

Eligibility and Restrictions for Use

Fenleve (fenfluramine) has a highly restricted eligibility profile established by governmental regulatory authorities due to the risk of valvular heart disease and pulmonary arterial hypertension.

Contraindications and Restrictions

Fenleve is formally contraindicated (must not be used) in patients who have:

  • A known hypersensitivity to fenfluramine or any of its inactive ingredients.
  • Used Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days, due to the risk of serotonin syndrome.

Specific Eligibility Constraints

Population Group Regulatory Status
Age Indicated for patients 2 years of age and older only.
Cardiac Status Not for use in patients with pre-existing valvular heart disease or pulmonary arterial hypertension. Use is conditional on regular echocardiogram assessments before, during, and after treatment.
Organ Function Not recommended for use in patients with moderate to severe renal impairment or hepatic impairment.
Distribution Available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program, which limits prescription and dispensing to certified healthcare providers and pharmacies.

Eligibility for Fenleve is strictly defined by these mandated exclusions and the requirement for patient enrollment in the restricted distribution program.

What should I know about interactions with other medicines?

Fenleve Interactions with other Medicines and Products

Fenleve (Ketoprofen) has documented interactions that primarily relate to bleeding risk, renal function, and alteration of drug plasma levels. Information regarding these interactions is detailed in official regulatory prescribing documents.

Documented Interaction Patterns

Classification Interacting Substances / Conditions
Formally Contraindicated Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), High-Dose Salicylates, and use for peri-operative pain during Coronary Artery Bypass Graft (CABG) surgery [FDA/EMA].
Increased Bleeding Risk Oral Anticoagulants (e.g., Warfarin), Heparins, and Anti-platelet agents (e.g., Clopidogrel), which pose a synergistic risk for gastrointestinal hemorrhage.
Exposure and Clearance Changes Lithium and Methotrexate (doses > 15 mg/week), whose renal clearance is reduced, increasing their blood levels and potential for toxicity. Probenecid also increases Ketoprofen exposure by reducing its clearance.
Effect on Other Drugs Diuretics and ACE Inhibitors/ARBs, which may have their antihypertensive effect diminished and carry an increased risk of renal failure.

Restrictions and Special Considerations

A mandatory timing rule applies to high-dose Methotrexate, which must be separated from Fenleve administration by at least 12 hours. Co-ingestion of alcohol is documented to increase the risk of stomach bleeding. In populations such as the elderly and patients with chronic liver disease, pharmacokinetics may be altered, and the risk of serious adverse events is heightened.

Mechanism of Action

Fenleve (Ketoprofen) works exclusively by targeting the underlying biological cascades responsible for generating excessive chemical messengers associated with nociception and acute inflammatory processes. This action is rooted in the molecule's ability to modulate the eicosanoid synthesis pathway.

Inhibition of the Cyclooxygenase (COX) Pathway

Fenleve primarily acts by functioning as a reversible, non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). This molecular action stops the conversion of Arachidonic acid into various prostaglandins, which are key chemical mediators of inflammatory and nociceptive signaling. This engagement of enzyme-mediated signaling is the foundational step that initiates the drug's physiological effects.

Central and Peripheral Modulation of Nociception and Thermoregulation

The suppression of prostaglandin synthesis affects two critical systems. Peripherally, reduced prostaglandin levels prevent the sensitization of nociceptors (pain receptors), thereby reducing the transmission of peripheral nociceptive input. Centrally, the mechanism reduces Prostaglandin E2 ( PGE2) in the hypothalamus, allowing the body's elevated temperature set-point to return toward its baseline. These cascading effects lead to predictable physiological adjustments that mediate signaling activity within the body's nociceptive and thermal regulatory pathways.

Dosage and Administration Information

How Fenleve is Used: Official Administration Guidelines

Fenleve (Ketoprofen) is a medicine designated for oral administration. Its usage is governed by the specific formulation, which dictates the official dosing frequency and protocol. The medication is available in two primary forms: immediate-release (IR) capsules and modified-release (ER) capsules.

Official Dosing and Frequency Patterns

The immediate-release form is used when multiple divided doses are required daily, such as 75 mg three times daily, with a maximum daily intake of 300 mg. The IR form is also used on an as-needed (p.r.n.) basis for short-term management of acute pain. In contrast, the extended-release formulation is typically reserved for long-term maintenance, utilized as a single 200 mg dose once daily.

Key Administration Instructions

Administration Aspect Official Instruction Summary
Intake Context Fenleve may be taken with food, milk, or antacids to minimize potential gastrointestinal discomfort.
ER Capsule Handling The Extended-Release capsule must be swallowed whole. It should never be crushed, chewed, or broken, as this alters the controlled-release mechanism.
Dose Adjustments Older adults and patients with renal or hepatic impairment are directed to start with a reduced initial dosage, maintaining the lowest effective dose for the shortest duration necessary.

General Usage Principle

These instructions define the standardized approach to using the medicine. If a dose is missed, patients should take the next scheduled dose at the usual time and should not double the dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Mechanism of Action and Efficacy Studies

The drug is an analgesic classified as a non-opioid. Research has explored whether it affects pain signaling via a proposed mechanism of action involving prostaglandins. Clinical studies have explored the timing of pharmacological activity and the length of the period over which activity was observed on pain severity in adults experiencing pain. Research has also investigated whether its use influences the quality of recovery after surgery and affects pain levels, potentially impacting the need for supplemental opioid rescue medication.

Use in Combination Therapy

Studies examining the drug's use in combination with other analgesic medicines have been conducted. The evaluation of combination use involved assessing whether the concurrent use of non-opioid medications affects pain control outcomes. These findings support the investigation of multimodal pain management approaches.

Types of Pain and Patient Groups Studied

Studies have evaluated the use of the drug in managing both acute (sudden, short-term) and chronic (long-term) pain states. Furthermore, research has explored its specific role in post-operative pain management.

Studies have also evaluated the drug's use in specific patient populations, including people with certain pre-existing conditions, such as liver disease. Specific research has examined the potential for toxicity in these groups. The studies included evaluation of common side effects, such as nausea, headache, and abdominal discomfort.

Frequently Asked Questions (FAQ)

Common questions about Fenleve (FAQ)

Q: What is Fenleve used for?

Fenleve is a prescription medication primarily used to manage certain types of chronic pain. It is a member of the opioid analgesic class of drugs, which work in the brain and nervous system to change how the body feels and responds to pain.

Q: How should I take Fenleve?

Fenleve is typically administered as a patch applied to the skin. The patch releases the medication slowly and continuously over a period of time, usually 72 hours. It is essential to follow the exact application instructions provided by your doctor or pharmacist. Do not cut, chew, or crush the patch.

Q: What are the common side effects of Fenleve?

Common side effects can include drowsiness, dizziness, constipation, and nausea. If these effects are severe or persistent, speak to your healthcare provider.

Q: Can I stop taking Fenleve suddenly?

No. Do not stop using Fenleve suddenly without consulting your healthcare provider. Stopping abruptly can cause withdrawal symptoms. Your doctor will provide a schedule to slowly reduce your dose over time to stop the medication safely.

Q: What should I avoid while using Fenleve?

You should avoid drinking alcohol and using other medications that cause drowsiness, such as sedatives or tranquilizers, while taking Fenleve. Combining these substances can increase the risk of serious side effects, including severe drowsiness and breathing problems.

How should Fenleve be stored and disposed of?

The official regulatory documents specify strict conditions for the storage and disposal of Fenleve (Ketoprofen Oral Capsules).

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF).
Protection Keep the container tightly closed and protect the medicine from excessive heat and moisture (e.g., avoid storing in the bathroom).
Container Keep the medicine in its original container until use.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Fenleve must be disposed of according to official regulatory guidance. The best option is typically to utilize an authorized drug take-back program or permanent collection site. If such options are unavailable and the medicine is not on the specific regulatory flush list, it must be prepared for household trash by mixing with an undesirable substance (e.g., dirt, kitty litter) and placing the mixture in a sealed bag or container. The medicine must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Fenleve found in:

A-Z Index: